Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy
Abstract Background Rituximab (RTX) is known to be effective in the treatment of idiopathic membranous nephropathy (IMN), but the specific dosing regimens have not been standardized. The aim of this retrospective study was to assess the clinical efficacy and safety of a B-cell-driven RTX regimen for...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00954-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389289158213632 |
|---|---|
| author | Kaiqi Guo Huaxia Zhu Xingcheng Xu Lanlan Huang Huimin Li Xiaowei Li |
| author_facet | Kaiqi Guo Huaxia Zhu Xingcheng Xu Lanlan Huang Huimin Li Xiaowei Li |
| author_sort | Kaiqi Guo |
| collection | DOAJ |
| description | Abstract Background Rituximab (RTX) is known to be effective in the treatment of idiopathic membranous nephropathy (IMN), but the specific dosing regimens have not been standardized. The aim of this retrospective study was to assess the clinical efficacy and safety of a B-cell-driven RTX regimen for the treatment of refractory IMN. Methods The data of 24 refractory IMN patients who underwent a B-cell-driven RTX regimen at Fuyang People’s Hospital of Anhui Medical University between October 2018 and November 2021 were retrospectively analysed. Results In total, 24 patients, comprising 17 males, with a mean age of 52.17 ± 8.28 years, were enrolled. After treatment with the B-cell-driven RTX regimen, 4 (16.67%) patients achieved complete remission, 11 (45.83%) patients achieved partial remission, the overall treatment efficacy was 62.50%, and there were 4 (16.67%) cases of relapse. The cumulative remission RTX dose was 2.40 g (IQR, 2.10 to 3.50), and the total cumulative RTX dose was 2.85 g (IQR, 2.40 to 4.20). B-cell depletion was achieved in 23 (95.83%) patients after the first dose of RTX was applied and in 1 patient after the second dose of RTX was applied. There was a significant difference in clinical remission between patients with and without a change in anti-PLA2R antibody status from positive to negative (P < 0.001). Two (8.33%) patients experienced infusion reactions, and 5 (20.83%) patients experienced nonserious infections. Treatment was discontinued in one patient due to severe pneumonia. Conclusion A B-cell-driven RTX regimen can induce partial or complete remission in patients with refractory IMN and is safe. Clinical trial number Not applicable. |
| format | Article |
| id | doaj-art-cf21bceafdf94ba4ae0a8693f071fe6b |
| institution | Kabale University |
| issn | 2050-6511 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pharmacology and Toxicology |
| spelling | doaj-art-cf21bceafdf94ba4ae0a8693f071fe6b2025-08-20T03:42:00ZengBMCBMC Pharmacology and Toxicology2050-65112025-07-012611710.1186/s40360-025-00954-8Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathyKaiqi Guo0Huaxia Zhu1Xingcheng Xu2Lanlan Huang3Huimin Li4Xiaowei Li5Department of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityDepartment of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityDepartment of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityDepartment of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityDepartment of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityDepartment of Nephrology, Fuyang People’s Hospital of Anhui Medical UniversityAbstract Background Rituximab (RTX) is known to be effective in the treatment of idiopathic membranous nephropathy (IMN), but the specific dosing regimens have not been standardized. The aim of this retrospective study was to assess the clinical efficacy and safety of a B-cell-driven RTX regimen for the treatment of refractory IMN. Methods The data of 24 refractory IMN patients who underwent a B-cell-driven RTX regimen at Fuyang People’s Hospital of Anhui Medical University between October 2018 and November 2021 were retrospectively analysed. Results In total, 24 patients, comprising 17 males, with a mean age of 52.17 ± 8.28 years, were enrolled. After treatment with the B-cell-driven RTX regimen, 4 (16.67%) patients achieved complete remission, 11 (45.83%) patients achieved partial remission, the overall treatment efficacy was 62.50%, and there were 4 (16.67%) cases of relapse. The cumulative remission RTX dose was 2.40 g (IQR, 2.10 to 3.50), and the total cumulative RTX dose was 2.85 g (IQR, 2.40 to 4.20). B-cell depletion was achieved in 23 (95.83%) patients after the first dose of RTX was applied and in 1 patient after the second dose of RTX was applied. There was a significant difference in clinical remission between patients with and without a change in anti-PLA2R antibody status from positive to negative (P < 0.001). Two (8.33%) patients experienced infusion reactions, and 5 (20.83%) patients experienced nonserious infections. Treatment was discontinued in one patient due to severe pneumonia. Conclusion A B-cell-driven RTX regimen can induce partial or complete remission in patients with refractory IMN and is safe. Clinical trial number Not applicable.https://doi.org/10.1186/s40360-025-00954-8RituximabMembranous nephropathyB-cell-drivenImmunosuppressant |
| spellingShingle | Kaiqi Guo Huaxia Zhu Xingcheng Xu Lanlan Huang Huimin Li Xiaowei Li Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy BMC Pharmacology and Toxicology Rituximab Membranous nephropathy B-cell-driven Immunosuppressant |
| title | Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| title_full | Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| title_fullStr | Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| title_full_unstemmed | Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| title_short | Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| title_sort | efficacy and safety of a b cell driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy |
| topic | Rituximab Membranous nephropathy B-cell-driven Immunosuppressant |
| url | https://doi.org/10.1186/s40360-025-00954-8 |
| work_keys_str_mv | AT kaiqiguo efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy AT huaxiazhu efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy AT xingchengxu efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy AT lanlanhuang efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy AT huiminli efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy AT xiaoweili efficacyandsafetyofabcelldrivenrituximabregimenforthetreatmentofrefractoryidiopathicmembranousnephropathy |